

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-022024-000630

Date: 29/02/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

1. For the 4 months from September to December 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab - Ongavia

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab - Ongavia

Response

Q1.

Injection Type	Count
Beovu	8
Eylea	597
Faricimab	891
Iluvien	1
Lucentis	598
Ozurdex	39
2134	

Q2.

Injection Type	First Time Count
Eylea	24
Faricimab	128
Lucentis	5
Ozurdex	15
172	

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow

Ref: FOI-022024-000630

Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust